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Progression through the early G1 phase of the cell
cycle requires mitogenic stimulation, which ultimately
leads to the activation of cyclin-dependent kinases 4 and
6 (Cdk4/6). Cdk4/6 activity is promoted by D-type cyclins
and opposed by Cdk inhibitor proteins. Loss of c-myc
proto-oncogene function results in a defect in the acti-
vation of Cdk4/6. c-myc/ cells express elevated levels of
the Cdk inhibitor p27Kip1 and reduced levels of Cdk7, the
catalytic subunit of Cdk-activating kinase. We show
here that in normal (c-myc/) cells, the majority of cy-
clin D-Cdk4/6 complexes are assembled with p27 and
remain inactive during cell cycle progression; their
function is presumably to sequester p27 from Cdk2 com-
plexes. A small fraction of Cdk4/6 protein was found in
lower molecular mass catalytically active complexes.
Conditional overexpression of p27 in c-myc/ cells
caused inhibition of Cdk4/6 activity and elicited defects
in G0-to-S phase progression very similar to those seen
in c-myc/ cells. Overexpression of cyclin D1 in c-myc/
cells rescued the defect in Cdk4/6 activity, indicating
that the limiting factor is the number of cyclin D-Cdk4/6
complexes. Cdk-activating kinase did not rescue Cdk4/6
activity. We propose that the defect in Cdk4/6 activity in
c-myc/ cells is caused by the elevated levels of p27,
which convert the low abundance activable cyclin
D-Cdk4/6 complexes into unactivable complexes con-
taining higher stoichiometries of p27. These observa-
tions establish p27 as a physiologically relevant regula-
tor of cyclin D-Cdk4/6 activity as well as mechanistically
a target of c-Myc action and provide a model by which
c-Myc influences the early-to-mid G1 phase transition.
D-type cyclins are the first cyclins to be expressed during the
early-to-mid G1 phase of the cell cycle (1). Cyclin D-Cdk4/6
1
complexes are believed to mediate a key signaling connection
between the extracellular environment and the intrinsic cell
cycle clock. Inappropriate activation of cyclin D-Cdk4/6 com-
plexes and the consequent hyperphosphorylation of the retino-
blastoma protein (Rb) are common events in a variety of human
tumors (2, 3). The activation of cyclin E-Cdk2 complexes has
been implicated as the major function of cyclin D-Cdk4/6 com-
plexes (4). The activation process of cyclin E-Cdk2 complexes
by cyclin D-Cdk4/6 has been shown to involve both catalytic
and stoichiometric mechanisms, viz. the phosphorylation of Rb
and the sequestration of the Cdk inhibitors p21Cip1 and
p27Kip1, respectively (1). In normal cells, however, both cyclin
D-Cdk4/6 and cyclin E-Cdk2 complexes appear to be required
in sequential fashion to elicit the hyperphosphorylation and
inactivation of Rb (5).
The expression of the c-myc proto-oncogene is closely corre-
lated with proliferation, and removal of growth factors at any
point in the cell cycle results in its prompt down-regulation (6,
7). c-myc is not expressed in quiescent cells, but is rapidly
induced by growth factors (8, 9); and ectopic expression in
quiescent cells can elicit entry into S phase (10, 11). Overex-
pression of c-Myc in growing cells leads to reduced growth
factor requirements and a shortened G1 phase (12), whereas
reduced expression causes lengthening of the cell cycle (13).
c-Myc has been likened to a cell-autonomous rheostat, with
engineered changes in its expression resulting in incremental
changes in proliferation largely independent of the outside
environment (14).
A striking parallel between the cyclin D and c-Myc pathways
is that both act as growth factor sensors by channeling envi-
ronmental cues to drive the cell cycle engine. However, the
manner in which they may be mechanistically connected is not
understood. We used gene targeting to eliminate c-myc expres-
sion in an immortalized rat fibroblast cell line (15). The
c-myc/ cells are viable, but display a significant lengthening
of both G1 and G2, resulting in a 3-fold reduced proliferation
rate. Analysis of key cell cycle regulatory components showed
that the absence of c-Myc coordinately reduced the activity of
all cyclin-Cdk complexes (16). The expression of the p27 protein
was elevated 2–3-fold, and the expression of Cdk7 was reduced
by a similar factor. During entry of quiescent cells into the cell
cycle, the earliest and largest defect was a 10-fold reduction
of cyclin D-Cdk4/6 activity, which resulted in a significant
delay in the phosphorylation of Rb. Although the expression of
Cdk4 is reduced in c-myc/ cells (17), the defect in Cdk4/6
activity during the G0-to-S phase transition is significantly
greater (16). In this study, we report an analysis of the role of
p27 and Cdk7 in the regulation of Cdk4/6 activity in the pres-
ence and absence of c-Myc.
MATERIALS AND METHODS
Cell Lines and Culture Conditions—TGR-1 is a subclone of the Rat-1
cell line, and HO15.19 is a c-myc-null derivative constructed by sequen-
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tial gene targeting (15). HO15.19 derivatives expressing ectopic cyclin
D1 were constructed by retrovirus vector transduction of full-length
murine or human cyclin D1 cDNA (16). Rat1p27 cells express p27 under
the control of the tTA (18) and were obtained from Bruno Amati (19).
Cultures were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% calf serum at 37 °C in an atmosphere of 5% CO2.
Rat1p27 cells were grown in the presence of 2 g/ml tetracycline to
block the expression of p27. Great care was taken that cultures were
cycling asynchronously and were in a rapid and exponential phase of
growth. Briefly, cells were always split at subconfluent densities
(50%) and at relatively low dilution (1:10 for c-myc/ and 1:4 for
c-myc/ cells). Cultures can thus be maintained continuously at den-
sities of 10–50% confluence (to avoid any contact inhibition), and the
relatively frequent passaging (every 3–4 days) and media changes
maintain a rapid growth rate. This regimen was followed for a mini-
mum of two passages before cells were harvested for biochemical ex-
periments. In G0 synchronization experiments, Rat1p27 cells were
trypsinized and replated in the presence of 2 g/ml tetracycline (p27-
OFF condition) or 0 g/ml tetracycline (p27-ON condition) 12–16 h prior
to serum starvation (0.25% calf serum), which was initiated in 95%
confluent cultures and maintained for 48 h. To induce cell cycle re-
entry, cells were trypsinized and replated at 50% confluence in the
presence of 10% calf serum. Tetracycline concentrations were kept
constant throughout the starvation and restimulation periods. Flow
cytometry was performed as indicated (15). Labeling of cells with CFSE
was performed as described (20, 21). Cells were labeled in suspension
for brief periods of time (5 min) and then replated under standard
exponential phase culture conditions. Cells were cultured for a mini-
mum of one cell cycle (24 h for c-myc/ and 48 h for c-myc/ cells) to
allow the clearing of unincorporated dye before the dye dilution exper-
iments were commenced.
Immunoblotting and Antibodies—Samples for immunoblotting were
prepared by direct rapid lysis in Laemmli sample buffer and analyzed
as described (14, 16, 22). The sources of antibodies were as follows:
Pharmingen, Rb (14001A); and Santa Cruz Biotechnology, cyclin D1
(sc-450), cyclin A (sc-596), cyclin B1 (sc-245), Cdk4 (sc-260), Cdk2
(sc-163), Cdk6 (sc-177), and p27 (sc-528 and sc-1641).
Immunoprecipitation Kinase Assays—Kinase assays were performed
as described (16, 23). Briefly, cultures at the indicated time points were
harvested with trypsin; washed with ice-cold Dulbecco’s phosphate-
buffered saline; and lysed for 2 h at 4 °C in buffer containing 50 mM
HEPES (pH 8), 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 1 mM
dithiothreitol, 10% glycerol, 0.1% Tween 20, and protease and phospha-
tase inhibitors. Protein concentrations were determined with the Bio-
Rad protein assay. Cyclin D1 was immunoprecipitated from 500 g of
extract with 1 g of anti-cyclin D1 antibody and 20 l of Gammabind
G-Sepharose beads (Amersham Biosciences). Cdk2 was immunoprecipi-
tated from 200 g of extract with 1 g of anti-Cdk2 antibody and 20 l
of protein A-agarose beads (Sigma). 1 g of glutathione S-transfer-
ase-Rb (24) and 2 g of histone H1 (Roche Molecular Biochemicals) were
used as substrates to assay Cdk4 and Cdk2 activities, respectively.
Kinase reactions were displayed by SDS-PAGE and analyzed with a
PhosphorImager. CAK activation assays of Cdk4 and Cdk2 complexes
were performed as described (16).
Size Exclusion Chromatography—TGR-1 or HO15.19 cultures in ex-
ponential growth were lysed as described for kinase assays. 1 mg of
total protein (300 l of extract) was chromatographed on a Superdex
200 column (24-ml bed volume) using a fast protein liquid chromatog-
raphy system (Amersham Biosciences) at a flow rate of 0.5 ml/min. The
column was run in lysis buffer and calibrated with gel filtration stand-
ards (Bio-Rad). 500-l fractions were collected; 80 l of each fraction
was analyzed by immunoblotting, and the remainder was immunopre-
cipitated and assayed for Cdk kinase activity as described above.
RESULTS
The Majority of Cdk4 Is Found in Inactive Complexes in Both
c-myc/ and c-myc/ Cells—The composition and activity of
cyclin D1-Cdk4 complexes were examined in growing c-myc/
and c-myc/ cells by size exclusion chromatography. Both
cultures were cycling asynchronously in a rapid and exponen-
tial phase of growth (see “Materials and Methods”). Column
fractions were immunoprecipitated with anti-cyclin D1 anti-
body; assayed for Cdk4 kinase activity; and then immuno-
blotted with antibody to cyclin D1, Cdk4, or p27 (Fig. 1). In both
c-myc/ and c-myc/ cells, the Cdk4 and cyclin D1 proteins
coeluted as a broad peak between 50 and 200 kDa. The p27
protein eluted as a sharper peak between 100 and 200 kDa.
Cdk4 activity peaked in two fractions between 70 and 100 kDa
and was reduced 3-fold in c-myc/ cells. The elution profile
of Cdk6 was the same as that of Cdk4 (data not shown). The
Rat-1 cells under study here express very low levels of cyclins
D2 and D3 (16), which precluded their analysis.
Densitometric analysis of the immunoblots revealed that in
c-myc/ cells, 80% of the Cdk4 protein was found in 125–
200-kDa complexes that were catalytically inactive and comi-
grated with the peak of the p27 protein. p27 thus appears to be
capable of both binding and inhibiting the activity of cyclin
D1-Cdk4 complexes. Only a relatively small fraction of the
Cdk4 protein (20%) was found in lower molecular mass
(70–100 kDa) catalytically active complexes that migrated ad-
jacent to the major peak of the Cdk4, cyclin D1, and p27
proteins. Although the resolution of the columns did not allow
us to determine whether the lower molecular mass catalytically
active complexes were free of p27 or contained low stoichiom-
etries of p27, several reports in the literature indicate that both
p27 and p21 promote the assembly of cyclin D-Cdk4/6 com-
plexes at low stoichiometries without inhibiting the Rb kinase
activity, but inhibit the activity at higher stoichiometries
(25–27). The c-myc/ elution profile contained clearly elevated
levels of p27, and the peak was broader. The levels of both the
cyclin D1 and Cdk4 proteins were also slightly elevated in
c-myc/ cells despite the fact that the mRNAs are down-
regulated (16, 17), suggesting that p27 stabilizes cyclin
D1-Cdk4 complexes. This observation is consistent with previ-
ous reports that the half-life of the cyclin D1 protein is in-
creased in both p27 and p21 complexes (27–29).
A recent report indicates that c-Myc may affect the frequency
of productive cell cycles (30). This raises the possibility that the
cultures under examination here may be mixtures of cycling
and non-cycling cells and that the observed changes in Cdk4
activity may be caused by variable fractions of cycling cells. To
address this issue, we performed a careful analysis of prolifer-
ation rates (Fig. 1B); the resultant growth curves show that
both cultures were kinetically in exponential phase. Only if a
constant fraction of cells were leaving the cycle at each division
would the bulk culture still give the appearance of exponential
kinetics. To further examine whether the cultures were com-
posed of discrete cohorts of cycling and non-cycling cells, we
monitored the dilution of the vital dye CFSE for several days
under our standard exponential phase growth conditions.
CFSE is a fluorescent dye that penetrates cell membranes and
is metabolized and trapped within cells. The dye is evenly
distributed to daughter cells, so fluorescence intensity de-
creases by half with each cell division. This method has been
widely used in immunology (31) and neurobiology (32) to track
cells both in vitro and in vivo for up to 10 generations. Dye
dilution was found to be completely uniform in both c-myc/
and c-myc/ cell lines (Fig. 1C). In this experiment, cohorts of
non-cycling (or slowly cycling) cells would be visualized as
discrete peaks (or shoulders) at higher fluorescence intensity
values. However, the peaks were found to be symmetrical and
of the same width in both cultures at all time points. Further-
more, the rate of dye dilution (decrease in fluorescence inten-
sity as a function of time) was completely consistent with the
doubling times measured by standard growth curves. We there-
fore conclude that under our conditions, both c-myc/ and
c-myc/ cultures are uniformly composed of continuously
cycling cells.
Because the majority of assembled cyclin D1-Cdk4 com-
plexes in normal (c-myc/) cells appeared to be catalytically
inactive, we examined the assembly and activation process
during entry into S phase. Quiescent cells were induced to
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enter the cell cycle; and samples were collected at 2-h intervals,
immunoprecipitated with anti-cyclin D1 antibody, assayed for
Rb kinase activity, and then immunoblotted with antibodies to
the known components of the complexes (Fig. 2). The cyclin D1,
Cdk4, and p27 proteins appeared abruptly and concomitantly
in the immunoprecipitates at the 6-h time point. This time
coincides with the induction of cyclin D1 mRNA expression
(16). The proliferating cell nuclear antigen and Cdk6 proteins
appeared in the cyclin D1 immunoprecipitates with kinetics
that followed closely those of Cdk4 and p27 (data not shown). In
contrast, the appearance of Rb kinase activity was significantly
delayed and was not fully induced until the 12-h time point in
c-myc/ cells (Fig. 2A, left panel). Examination of c-myc/
cells revealed a very similar profile, except that the abundance
of all the components was somewhat increased and that the Rb
kinase activity was greatly reduced (Fig. 2B, left panel). A
densitometric quantification of the immunoblots of cyclin D1,
Cdk4, and p27 revealed that all proteins were present in the
immunoprecipitates at low basal levels in quiescent cells and
remained relatively constant at the 2- and 4-h time points (Fig.
FIG. 1. Composition and activity of cyclin D-Cdk4 complexes in cycling cells. A, gel filtration profiles. Extracts of exponentially growing
c-myc/ and c-myc/ cells were chromatographed on a Superdex 200 column. Cultures were kept continuously in exponential phase growth for
a minimum of six doublings prior to harvest. Individual fractions were immunoprecipitated with anti-cyclin D1 antibody and either immunoblotted
as indicated or assayed for Rb kinase activity (32P-Rb). The experiment was repeated three times with consistent results. CycD1, cyclin D1. B,
proliferation profiles of exponentially cycling cultures. Growth curves were generated on cultures maintained under the conditions described for
A. Curve fits of the experimental data points yielded exponential functions with R2 values of 0.997 and 0.975 for c-myc/ and c-myc/ cells,
respectively. Doubling times calculated from these functions were 20.5 and 52 h for c-myc/ and c-myc/ cells, respectively. C, CFSE dye dilution
profiles of exponentially cycling cultures. Cultures maintained in exponential phase under the conditions described for A were labeled with CFSE
and replated at 20–30% confluent densities. Dye dilution was monitored on successive days (d) using flow cytometry. The mean intensity values
of the peaks (in arbitrary units) were as follows: for c-myc/ cells, 22 (day 1) and 3 (day 3); and for c-myc/ cells, 21 (day 2), 14 (day 3), and
9 (day 4). The calculated dye dilution half-times for these values are 16 h (c-myc/ cells) and 40 h (c-myc/ cells).
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2, A and B, right panels). The maximum induction ratios were
as follows: cyclin D1, 7-fold in c-myc/ cells and 11-fold in
c-myc/ cells; Cdk4, 6-fold in c-myc/ cells and 9-fold
in c-myc/ cells; and p27, 19-fold in c-myc/ cells and 48-fold
in c-myc/ cells. Gel filtration chromatography of extracts
collected at the time of peak activity (12–14 h) revealed profiles
very similar to those shown in Fig. 1 (data not shown). c-myc/
and c-myc/ cells express equivalent amounts of the Cdk
inhibitors p15INK4b and p16INK4a (19), and neither express
detectable levels of p18INK4c and p19INK4d (data not shown).
These results are consistent with the hypothesis that the ma-
jority of the newly synthesized cyclin D1 protein is rapidly
assembled with Cdk4/6 and multiple molecules of p27. Of par-
ticular interest is the observation that complexes are appar-
ently fully assembled at early times, but not activated until
much later. The fact that the complexes are eventually acti-
vated without significant changes in overall stoichiometry fur-
ther corroborates the interpretation that only a small fraction
of total complexes become catalytically active.
Conditional Overexpression of p27 Results in a Phenotype
Resembling Loss of c-Myc—The observation that the majority
of cyclin D1-Cdk4/6 complexes appear to be bound by multiple
molecules of p27 and are not activated even in c-myc/ cells
predicts that increasing the p27 pool will inhibit the remaining
active complexes. Transient overexpression of p27 has been
shown to cause G1 arrest (33). A stable Rat-1-derived cell line,
Rat1p27 (19), in which p27 expression is controlled by the
tTA tetracycline-controlled transactivator (18), proliferates
normally in the presence of 2 g/ml tetracycline. Withdrawal
of tetracycline, which induces p27 expression, reduced prolif-
eration 2-fold (data not shown). To analyze the conse-
quences of elevated p27 expression during progression from
G0 to S phase, it was necessary to prepare quiescent cells
with increased levels of p27. This was accomplished by re-
moving tetracycline from the medium 12–16 h prior to as well
as during a standard 48-h serum deprivation period. Cells
thus treated were quiescent and displayed maximum p27
induction. Cell cycle re-entry was elicited by serum stimula-
tion in the continued absence of tetracycline. Control cultures
were treated identically, but were supplemented with 2 g/ml
tetracycline throughout the regimen to keep the p27 trans-
gene inactive.
Analysis of cell cycle progression by flow cytometry (Fig. 3, A
and B) showed normal S phase entry in the presence of tetra-
cycline (p27-OFF) at 12 h after serum stimulation, the same as
in parental Rat-1 cells. In the absence of tetracycline (p27-ON),
the S phase peaks were significantly diminished as well as
delayed to 16–18 h. This profile was similar to that seen in
c-myc/ cells, which began to enter S phase at 20–22 h. As
previously reported (15), bromodeoxyuridine labeling analyses
showed that the entire cell population was delayed in S phase
entry and that entry was spread over a longer time period,
rather than a portion of the culture failing to enter the cell
cycle. Immunoblot analysis of Rat1p27 cells showed clearly
elevated levels of the p27 protein in quiescent cells in the
absence of tetracycline (p27-ON), but not in its presence (p27-
OFF) (Fig. 3C). The elevated levels of p27 under the p27-ON
condition persisted for24 h after serum stimulation, but were
reduced at later times, which may account for the leakiness of
the block and continued proliferation in the absence of tetra-
cycline, albeit at reduced rates. In agreement with the previous
results, the levels of cyclin D1 were also noticeably increased in
the presence of elevated p27.
Given that increased p27 expression impeded S phase entry,
we investigated the extent to which the molecular landmarks of
this transition resembled those seen in c-myc/ cells. The
absence of c-Myc during the G0-to-S phase transition results in
significantly reduced (10-fold) Cdk4/6 activity, delayed phos-
phorylation of Rb, delayed and dampened activation of Cdk2,
and delayed induction of cyclin A (16). Under the p27-OFF
condition, the onset of Rb phosphorylation was first evident at
4 h, whereas under the p27-ON condition, significant Rb phos-
phorylation was minimum even at the 12-h time point (Fig.
3C). 24 h after serum stimulation, Rb phosphorylation was still
appreciably defective. In comparison, Rb phosphorylation is
first detectable at 8 h in c-myc/ cells and at 6 h in parental
c-myc/ cells (16). Rb phosphorylation thus appears to be even
more defective in the presence of excess p27 than in the
absence of c-Myc.
The composition and activity of Cdk4 complexes were exam-
ined during the G0-to-S phase transition under the p27-OFF
and p27-ON conditions and compared with the total expression
of the constituent proteins. Immunoblot analysis (Fig. 4A)
showed that total cyclin D1 levels were highest early in the
transition (6 h) and declined at later times (18 and 30 h) under
the p27-OFF condition; in the p27-ON cells, cyclin D1 levels
were elevated throughout and peaked at much later times (18
h). Cdk4 and Cdk2 levels were constant throughout the time
course under both conditions. Cdk2 showed a shift to higher
mobility indicative of CAK phosphorylation at 18 h in p27-OFF
cells, but not until 30 h in p27-ON cells. This result is consist-
ent with observations that p27 can antagonize the phosphoryl-
ation of Cdk complexes by CAK (34, 35). Immunoprecipitation
with anti-cyclin D1 antibody (Fig. 4B) from extracts of p27-OFF
cells showed the expected induction of cyclin D1 early in the
transition (6 h), and both the Cdk4 and p27 proteins were
efficiently co-immunoprecipitated at this time. Cdk4 activity
was strongly induced at later times. Under the p27-ON condi-
tion, cyclin D1-Cdk4 complexes were more abundant, were
present at high levels at much later times, and at all times
contained high levels of the p27 protein. The activity of the
complexes was low throughout, although a weak induction was
evident at 18 h. The defect in Cdk4 activation in the p27-ON
cells was 15-fold in this experiment.
FIG. 2. Assembly and activation of cyclin D1-Cdk4 complexes
during G0-to-S phase progression. A, c-myc
/ cells; B, c-myc/
cells. Cell cycle entry of quiescent cells was initiated at 0 h, and samples
were collected at the indicated time points. Left panels, extracts were
immunoprecipitated with anti-cyclin D1 antibody and either immuno-
blotted (IB) as indicated or assayed for Rb kinase activity (32P-Rb).
Right panels, the data in the left panels were subjected to densitometric
analysis. The experiment was repeated twice with consistent results.
CycD1, cyclin D1.
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A comparison of Cdk4 and Cdk2 activities and the induction
of cyclins A and B1 were monitored in a separate experiment
(Fig. 4C). In p27-OFF cells, strong induction of both Cdk4 and
Cdk6 activities was detected at 16 h, whereas neither activity
was apparent in p27-ON cells until 24 h. The defect in activa-
tion in p27-ON cells was 5–7-fold for both Cdk4 and Cdk2;
however, Cdk4 activity was barely elevated above the back-
ground level in p27-ON cells, whereas Cdk2 activity was sub-
stantially induced. Thus, the defect in activation is more pro-
nounced for Cdk4 than for Cdk2. Both cyclins A and B1 were
detected at 16 h in p27-OFF cells, but not until 24 h in p27-ON
cells. In summary, elevated levels of p27 cause a significant
delay in the G0-to-S phase transition that is characterized by a
strong defect in Cdk4 activation and Rb phosphorylation and a
delay in the activation of Cdk2 and the expression of cyclins A
and B1. These molecular phenotypes are very similar to those
caused by the absence of c-Myc (16).
Cyclin D1 (but Not Cdk7) Rescues Cdk4 Activity in c-myc/
Cells—The hypothesis that increased p27 expression contrib-
utes to the Cdk4 defect seen in c-myc/ cells by binding to the
small fraction of potentially activable cyclin D1-Cdk4/6 com-
plexes and converting them to unactivable complexes contain-
ing higher stoichiometries of p27 predicts that increasing the
pool of cyclin D will rescue Cdk4 activity by allowing the
assembly of additional complexes. To test this prediction, we
constructed numerous clonal cell lines ectopically expressing a
murine or human cyclin D1 transgene (16). All cell lines were
screened by immunoblotting for expression of the exogenous
cyclin D1 protein, and clones with a moderate level of overex-
pression were chosen. Kinase assays of two representative
clones showed that the increase in cyclin D1 expression com-
pletely rescued Cdk4 activity, but did not rescue Cdk2 activity
(Fig. 5A).
Cdk7 is expressed at reduced levels in c-myc/ cells (16).
Because cyclin D1-Cdk4/6 complexes in c-myc/ cells are as-
sembled at essentially normal levels in early G1, but subse-
quently fail to be activated, we investigated whether phospho-
rylation by CAK may be limiting. Cyclin D1-Cdk4/6 complexes
were immunoprecipitated from c-myc/ and c-myc/ cells at
successive times during the G0-to-S phase transition, incubated
with active recombinant CAK, and subsequently assayed for
Rb kinase activity (Fig. 5B). CAK did not increase the activity
of cyclin D1-Cdk4/6 complexes at any time point in either
c-myc/ or c-myc/ cells. The CAK preparation was catalyt-
ically active because it strongly activated purified recombinant
cyclin A-Cdk2 complexes under the same assay conditions.
CAK also activates native Cdk2 complexes immunoprecipi-
tated from Rat-1 cells (16). We also ectopically expressed Cdk7
in c-myc/ cells using the same strategy as that used for cyclin
D1. Stable clonal cell lines were isolated, and restoration of
Cdk7 expression levels to those seen in c-myc/ cells was
demonstrated by immunoblotting. However, in this case, nei-
FIG. 3. Conditional expression of p27 delays S phase entry and Rb phosphorylation. A and B, cell cycle entry of quiescent cells was
initiated at 0 h, and samples were collected at the indicated time points and analyzed by flow cytometry. C, Rat1p27 cells were treated as indicated
in A and B, and samples were analyzed by immunoblotting. tet, tetracycline; CycD1, cyclin D1.
FIG. 4. Composition and activity of Cdk4 and Cdk2 complexes under p27-ON and p27-OFF conditions. Cell cycle entry of quiescent
cells was initiated at 0 h, and samples were collected at the indicated time points. A, shown are the results from immunoblot analysis. CycD1, cyclin
D1. B, extracts were immunoprecipitated with anti-cyclin D1 antibody and either immunoblotted as indicated or assayed for Rb kinase activity
(32P-Rb). C, Cdk4 and Cdk2 activities were assayed in cyclin D1 immunoprecipitates (32P-Rb) and Cdk2 immunoprecipitates (32-H1), respectively.
The expression of p27, cyclin A (CycA), and cyclin B1 (CycB1) was determined by immunoblotting.
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ther the growth rate nor Rb phosphorylation was rescued (data
not shown).
DISCUSSION
During the entry of quiescent cells into the cell cycle, a
transition that is acutely dependent on strong and sustained
mitogenic signaling, the earliest and largest defect in c-myc/
cells is a 10-fold reduction of cyclin D-Cdk4/6 activity. The
magnitude of the activity defect cannot be explained by the
relatively modest effects on cyclin D1 and Cdk4 expression (16,
17). In fact, we show here that although c-myc-null cells as-
sembled slightly more cyclin D1-Cdk4/6 complexes than nor-
mal cells, the complexes remained largely inactive.
Several studies have indicated that members of the Cip/Kip
family of Cdk inhibitors are required for the assembly of cyclin
D-Cdk4/6 complexes (25–29, 36–38). The picture emerging
from in vitro studies is that both p27 and p21 promote the
assembly of the complexes at low (1:1) stoichiometries without
inhibiting the Rb kinase activity, but inhibit the activity at
higher stoichiometries (25–27). p27 can also interfere with the
activation of cyclin D-Cdk4/6 complexes by CAK. The experi-
ments reported here involving conditional expression of p27
show that elevated p27 expression can potently inhibit the in
vivo activity of cyclin D1-Cdk4/6 complexes. In fact, during
G0-to-S phase progression, elevated expression of p27 elicited a
remarkable molecular phenocopy of the c-myc loss-of-function
phenotype: an early large defect in Cdk4/6 activity, a delay in
Rb phosphorylation, a subsequent delay in the induction of
cyclin E and Cdk2 activities, and finally a delay in cyclin A
expression and S phase entry. Although both Cdk4/6 and Cdk2
activities were affected, the Cdk4/6 defect was earlier and
larger in magnitude, exactly as seen in c-myc-null cells.
It is likely that c-Myc can affect the expression level of the
p27 protein by several mechanisms. One mechanism is the
promotion of p27 degradation by ubiquitin-mediated proteoly-
sis (39). Because the degradation of p27 is triggered by cyclin
E-Cdk2 phosphorylation, it is unlikely that these mechanisms
are operative in early G1 at the time when cyclin D-Cdk4/6
complexes are being assembled and activated. c-Myc can also
influence the expression of the p27 mRNA, which is not down-
regulated normally in c-myc/ cells after mitogenic stimula-
tion of quiescent cells (16). This study did not, however, address
whether these effects are transcriptional or post-transcrip-
tional. Repression of some (but not all) genes by c-Myc has been
shown to involve the Inr promoter element (40); the p27 pro-
moter contains an Inr element, and one study suggested that
the repression of p27 by c-Myc may be mediated in part
through this site (41). However, the mechanisms by which
c-Myc affects the expression of the p27 gene need to be further
investigated.
How could a 3-fold increase in the steady-state level of the
p27 protein result in a10-fold defect in Cdk4/6 activity? A key
observation that shed light on this mechanism was that 80%
of the Cdk4/6 protein was found in inactive complexes that
contained high stoichiometries of p27. Gel filtration experi-
ments showed that Cdk4/6 migrated as a broad peak of 160
kDa that comigrated with the peak of cyclin D1. However, Rb
kinase activity migrated as a distinct peak of 70–100 kDa, and
the distribution of p27 was skewed toward the higher molecu-
lar mass inactive complexes. Although the resolution of the
columns did not allow us to determine whether the active
complexes were free of p27, it is clear that the higher molecular
mass complexes contained more abundant p27 (compare frac-
tions 16 and 13 in Fig. 1) and were inactive as Rb kinases.
Thus, even in c-myc/ cells, only a small fraction of the total
cyclin D-Cdk4/6 complexes become activated. The column pro-
file in c-myc/ cells was qualitatively very similar; but levels
of p27 were elevated, the peak was broader, and the kinase
activity of the 70–100-kDa fractions was reduced.
During the G0-to-S phase transition, cyclin D1 and Cdk4/6
were rapidly assembled in early G1 into complexes that con-
tained abundant p27, whereas the appearance of Rb kinase
activity was delayed by several hours. Again, c-myc/ cells
displayed the same profile; the abundance of Cdk4/6 complexes
was somewhat increased; and Rb kinase activity was greatly
reduced. The absence of a significant change in the stoichiom-
etry of the complexes in either c-myc/ or c-myc/ cells dur-
ing the activation process suggests that activation does not
involve rearrangement of the complexes, but is likely depend-
ent on additional events such as phosphorylation by CAK of
pre-existing complexes that contain a few (or no) molecules
of p27.
Taken together, the gel filtration data and the G0-to-S phase
induction profiles suggest the following model. Mitogenic sig-
naling induces the expression of cyclin D, which, with the aid of
p27, is rapidly assembled with Cdk4/6 and transported into the
nucleus. The majority of the nuclear cyclin D-Cdk4/6 complexes
are bound to multiple molecules of p27 and remain inactive
throughout G1. As previously suggested (1), the physiological
function of these complexes would be to eliminate the free pool
of p21 and p27 or even to actively sequester these Cdk inhibi-
tors from the low levels of cyclin E-Cdk2 complexes present in
early G1 to facilitate their subsequent activation. A small frac-
tion of cyclin D-Cdk4/6 complexes would be bound to only one
(or no) p27 molecule and could thus become activated later in
G1. The key prediction of this model is that even a modest
increase in overall p27 levels could convert a significant frac-
tion of the low abundance activable complexes into unactivable
complexes containing higher stoichiometries of p27.
This model is supported by the observation that even a
modest overproduction of cyclin D1 in c-myc/ cells can com-
pletely rescue complex activity. This is because cyclin D levels
are limiting for the assembly of cyclin D-Cdk4/6 complexes, and
overexpression of cyclin D1 results in the assembly of addi-
tional complexes. The observations that CAK activity is not
limiting for the activation of cyclin D1-Cdk4/6 complexes in
either c-myc/ or c-myc/ cells, that the expression of Cdc25A
is not affected in c-myc/ cells (42), and that the activation of
cyclin D1-Cdk4/6 complexes is initiated normally in both
FIG. 5. Effect of cyclin D1 and CAK on Cdk4 activity. A, the
indicated cell lines were grown exponentially, and extracts were as-
sayed for Cdk4 and Cdk2 activities as described in the legend to Fig. 4C.
The cell line hu-CycD1 (where hu is human, and CycD1 is cyclin D1)
was previously referred to as HO15D2 (16). The cell line mu-CycD1
(where mu is murine) was constructed in an analogous fashion. The
experiment was repeated twice with consistent results. B, cell cycle
entry of quiescent cells was initiated at 0 h; samples were collected at
the indicated time points; and extracts were immunoprecipitated with
anti-cyclin D1 antibody, incubated in the presence or absence of cata-
lytically active CAK, and subsequently assayed for Rb kinase activity.
Lower panel, activation of recombinant cyclin A-Cdk2 assayed by his-
tone H1 kinase activity.
p27 Acts Downstream of Myc to Inhibit Cdk4/6 Activity31268
 at U
N
IV
ERSID
A
D
 D
E O
V
IED
O
 on M
ay 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
c-myc/ and c-myc/ cells at the same time after serum
stimulation (12 h) (19) are all consistent with the interpreta-
tion that the major reason for the observed Cdk4/6 activity
defect is the assembly of fewer potentially active complexes.
Furthermore, in light of the recent report that the p21 gene is
silenced in Rat-1 cells by promoter methylation (43), this model
also provides an attractive explanation of why c-myc/ Rat-1
cells are capable of proliferation, albeit at greatly reduced
rates.
However, it also needs to be stressed that p27 is unlikely to
be the only c-Myc target relevant to regulation of cell cycle
progression. For example, although the expression of p27 in the
conditional Rat1p27 cell line was higher than that seen in
c-myc/ cells, the proliferation defect during either exponen-
tial growth or the G0-to-S phase transition was not as severe in
Rat1p27 cells as in c-myc/ cells. Similarly, if the only func-
tion of c-Myc were to promote the activity of Cdk4/6 complexes,
overexpression of cyclin D would be expected to rescue cell cycle
progression as well as Cdk2 activity, which is not the case.
Although CAK is not limiting for Cdk4/6 activity, it appears to
be limiting for Cdk2 activity (16) and may thus in part explain
the effects of c-Myc on cell cycle progression in late G1. The
facts that cyclin D1 overexpression rescues Cdk4/6 activity, but
cyclin E overexpression does not rescue Cdk2 activity, are in
agreement with this interpretation (data not shown). Further-
more, the lack of rescue by cyclin E is not consistent with the
possibility that the major bottleneck in c-myc/ cells is the
failure of cyclin D-Cdk4/6 complexes to sufficiently sequester
the elevated levels of p27. By extension, this would then argue
in favor of a functional role for Cdk4/6 catalytic activity during
G1 phase progression.
The function of the cyclin D pathway is subverted to a
greater or lesser extent in most (if not all) cancer cells and
derived cell lines. Given the importance of this signaling con-
nection between the extracellular environment and the intrin-
sic cell cycle clock, it is of interest that c-Myc regulates the
expression (17) as well as the activity of cyclin D-Cdk4/6 com-
plexes by multiple mechanisms. The work reported here estab-
lishes p27 as a physiologically relevant regulator of cyclin
D-Cdk4/6 activity as well as a target of c-Myc and provides a
mechanistic model by which c-Myc influences the early-to-mid
G1 phase transition. Additional targets of c-Myc relevant to cell
cycle regulation will undoubtedly be discovered; however, reg-
ulation of Cdk4/6 activity may provide a direct link between the
ability of c-Myc to promote tumorigenesis and cell cycle
progression.
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